Clinical characteristics of myelodysplastic syndromes and long-term therapeutic effects of amifostine combined with hematopoietic growth factors in elderly people
YU Rui-li
YANG Bo
CAI Li-li
CHI Xiao-hua
WANG Xue-yan
LU Xue-chun
Abstract：Objective: To investigate the clinical characteristics, therapeutic effects and factors affecting prognosis in elderly myelodysplastic syndromes (MDS) patients. Methods: A total of 24 elderly MDS patients who were admitted into our department from January 1998 to December 2015 were retrospectively analyzed. Epidemiological features, changes in blood indexes, World Health Organization (WHO) cancer classification and the International Prognostic Scoring System (IPSS) were summarized. Patients were divided into 4 groups according to their treatment. Hemoglobin levels, platelet counts and neutrophil counts were measured and compared before and after treatment. The survival of patients with refractory anemia was assessed using Cox model and the efficacy of different treatment protocols and the factors affecting prognosis were compared. Results: The results showed that average age of patients was 81 years, and all were male. Cardiovascular and cerebrovascular co-morbidities were commonly observed, while there were some other concurrent cancers. Among the cases, refractory anemia (RA) accounted for 79.2% and low-risk patients accounted for 87.5%. The 3-month efficacies of the traditional treatment protocol, administration of hematopoietic growth factor alone, administration of hematopoietic growth factor and amifostine and chemotherapy were 60%, 60%, 93% and 60%, respectively. Combined treatment of amifostine and hematopoietic growth factor effectively enhanced patients' 10-year survival rate. Hemoglobin levels after 3 months of treatment affected patients' survival rate. Conclusion: It is concluded that MDS occur more often in male elderly patients, in which refractory anemia is most commonly found. Low-risk patients represented the majority. Combined treatment using amifostine and hematopoietic growth factor effectively improve the long-term prognosis of MDS patients.
Keywords：Myelodysplastic syndromeElderly patientRefractory anemiaAmifostineHemopoietic growth factorSurvival rate
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 75-80 )